At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 419 enrolled
Drug / intervention
Ropinirole XL (formerly CR)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169
In Brief
A Phase 3 clinical trial evaluating Ropinirole XL (formerly CR) for Parkinson Disease and Parkinson's Disease. Completed, enrolled 419 participants across 75 sites in 9 countries.
Detailed Summary
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Parkinson's Disease
CountriesBelgium, Czechia, France, Hungary, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
First PostedMar 2008
Primary CompletionMar 2010
TodayJul 2026
First PostedMar 11, 2008
Enrollment StartFeb 1, 2004
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 18.3 years ago
Interventions
Ropinirole XL (formerly CR)drug